RRRobert Allyn Redd

Robert Allyn Redd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert Allyn Redd has a total of 738 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

    by Elizabeth K. O’DOnnell, Omar Nadeem, Jacob P. Laubach, Giada Bianchi, Andrew R. Branagan, Brea C. Lipe, Paul G. Richardson, Ehsan Malek, Robb S. Friedman, Ajay K. Nooka, et al.

  • Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

    by Noé Perron, Kane Foster, Tarek H. Mouhieddine, Robert A. Redd, Sophie Magidson, Jacqueline Perry, Ashlee Sturtevant, Christine Davie, Caroline Ricciardi, Frances Arters, et al.

  • Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data

    by Tulika Rudra Gupta, Mei-Yin C. Polley, Robert Redd, Eudocia Q. Lee, Isabel Arrillaga-Romany, Mark R. Gilbert, Yujue Tan, Mehdi Touat, Jan Drappatz, Mary R. Welch, et al.

    PURPOSE: Integrating external control data into clinical trial designs and analyses has the potential to accelerate drug development processes. We reanalyzed the three experimental arms of the Individual Screening Trial of Innovative Glioblastoma Therapy (INSIGhT), a randomized phase II platform trial in newly diagnosed O 6 -methylguanine-DNA methyltransferase-unmethylated glioblastoma (ClinicalTrials.gov identifier: NCT02977780 ). To evaluate the validity of using external data sets, we compared treatment effect estimates based on internal INSIGhT control data and matched external control data. METHODS: The three experimental arms of INSIGhT (abemaciclib [n = 72], neratinib [n = 80], and CC-115 [n = 12]) did not improve survival compared with internal controls (standard chemoradiation [n = 70]). We derived external control patient-level data from multiple real-world and clinical trial data sets. We applied propensity score matching and Cox proportional hazards models to estimate treatment effects with external controls. Additionally, using this glioblastoma (GBM) data collection, we specified simulation scenarios to evaluate trial designs that integrate external controls. RESULTS: After matching to external controls, no survival benefit was observed for patients receiving abemaciclib (hazard ratio [HR], 1.00 [95% CI, 0.75 to 1.34]), neratinib (HR, 0.93 [95% CI, 0.70 to 1.24]), or CC-115 (HR, 0.88 [95% CI, 0.41 to 1.88]). Simulations, together with the INSIGhT data and a collection of GBM data sets, allowed us to examine efficiencies and risks of clinical trial designs that leverage external control data. CONCLUSION: The use of carefully matched external controls, to replace or augment the internal controls of INSIGhT, produced treatment effect estimates that were similar to previously published analyses. Single-arm trial designs and hybrid randomized designs incorporating propensity score–matched external control data evaluated treatment effects in the early-phase testing of experimental therapies in newly diagnosed GBM. The validity of this approach and risks of bias depended on the availability of comprehensive and accurate data on all potential confounders, in the absence of unmeasured confounding.


  • Open Access

    A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma

    by J. Erika Haydu, Robert A. Redd, Matthew M. Lei, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Jacob D. Soumerai, April F. Eichler, Eric D. Jacobsen, Justin T. Jordan, et al.

    Synchronous systemic and de novo secondary central nervous system (CNS) large B-cell lymphoma (LBCL) is an aggressive clinical entity with a historically poor prognosis. Given the rarity of this presentation, prospective studies are limited, and treatment paradigms and outcomes are extrapolated from small, heterogenous retrospective studies. We performed a retrospective study with extended follow-up for 63 consecutive patients with previously untreated synchronous systemic and de novo secondary CNS LBCLs presenting to 2 institutions over 21 years. Most patients had diffuse LBCL (73%) and were treated with an average of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) intercalated with high-dose IV methotrexate (R-CHOP-M). The overall response rate was 84% (75% complete). With a median follow-up of 8.1 years, the median progression-free survival (PFS) was 1.2 years, and the 6-year PFS rate was 37%. The median overall survival (OS) was 7.9 years, and the 6-year OS rate was 52%. Normal lactate dehydrogenase (LDH), low International Prognostic Index (IPI) score, and brain parenchymal-only CNS disease were associated with improved PFS, whereas normal LDH and parenchymal disease were associated with OS. The 25% of patients who underwent consolidation with high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT) had superior PFS and OS than patients who did not receive a transplant, with particular benefit in those with IPI score of ≥3. This study demonstrates that a proportion of patients presenting with secondary CNS involvement are cured with upfront chemoimmunotherapy with or without HDC/ASCT and helps identify prognostically favorable subgroups, which can guide counseling of patients with this rare, high-risk clinical presentation.


  • Open Access

    Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism

    by Sirui Ma, Yu-Cheng Chang, Cho-Han Chiang, Junmin Song, Yu-Che Lee, Ko-Yun Chang, Robert A. Redd, Thita Chiasakul, Ellen P. McCarthy, Jeffrey I. Zwicker, et al.

    Venous thromboembolism (VTE) is a frequent occurrence in patients with cancer. However, it is not known whether treatment with different classes of anticoagulants impacts the risk of subsequent arterial thromboembolism. We performed a retrospective, population-based cohort study using Surveillance, Epidemiology, and End Results data linked with Medicare claims. Patients were eligible for study inclusion if they had a diagnosis of primary brain, colorectal, gastric, pancreatic, lung, or ovarian cancer between 2007 and 2015, were diagnosed with VTE, and had a prescription claim for a direct oral anticoagulant (DOAC), low-molecular-weight heparin (LMWH), or warfarin. We matched patients by propensity score in a 1:1:1 ratio into anticoagulant treatment groups based on their baseline demographic information, cancer-specific characteristics, and cardiovascular comorbidities. The primary aim of the study was to determine and compare the 6-month cumulative incidence of ischemic stroke across anticoagulant classes. The study comprised 4875 total patients with 1625 in each treatment group. At 6 months, the cumulative incidence of ischemic stroke was 5.6% (95% confidence interval [CI], 5.0-6.3) overall and 6.8% (95% CI, 5.6-8.1) in the DOAC, 4.9% (95% CI, 3.9-6.0) in the LMWH, and 5.2% (95% CI, 4.1-6.2) in the warfarin treatment groups (P = .040). We identified hypertension (odds ratio [OR], 1.75), atrial fibrillation/flutter (OR, 1.37), DOAC use (OR, 1.36), and previous stroke (OR, 3.59) as statistically significant risk factors for ischemic stroke in the multivariable modeling. In conclusion, ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.

  • Open Access

    Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma

    by Ye Zhang, Lydie Debaize, Adam Langenbucher, Jenalyn Weekes, Ioulia Vogiatzi, Teemu P. Miettinen, Mingzeng Zhang, Emily Sumpena, Huiyun Liu, Sarah M. Duquette, et al.

    Intratumor heterogeneity impacts disease progression and therapeutic resistance but remains poorly characterized by conventional histologic, immunophenotypic, and molecular approaches. Single-cell biophysical properties distinguish functional phenotypes complementary to these approaches, providing additional insight into cellular diversity. Here, we link both buoyant mass and stiffness to gene expression to identify clinically relevant phenotypes within primary mantle cell lymphoma (MCL) cells, using MCL as a model of biological and clinical diversity in human cancer. Linked measurements reveal that buoyant mass and stiffness characterize B cell development states from naïve to plasma cell and correlate with expression of oncogenic B cell receptor signaling genes such as BLK and CD79A . In addition, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton’s tyrosine kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.


  • Open Access

    Supplementary Tables from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

    by Elisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, Gabriela Brunsting Hoffmann, Michaela Gruber, Kendell Clement, Livius Penter, Robert A. Redd, Neil Ruthen, Sébastien Hergalant, et al.

    Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.

  • Open Access

    Supplementary Figures from In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

    by Elisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, Gabriela Brunsting Hoffmann, Michaela Gruber, Kendell Clement, Livius Penter, Robert A. Redd, Neil Ruthen, Sébastien Hergalant, et al.

    Supplementary file contains a PDF version of supplementary figures S1-S7 and associated figure legends.

  • Open Access

    Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma

    by Nira Krasnow, Katie Maurer, Catherine Song, Justin Rhoades, Kan Xiong, Andjela Crnjac, Timothy Blewett, Lily Gao, Heather Jacene, Reid Merryman, et al.

    Despite responses of chimeric antigen receptor (CAR)-T cells in patients with relapsed/refractory large B-cell lymphoma (LBCL), over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify patients at high risk of treatment failure. We recently developed MAESTRO, an ultrasensitive, tumor-informed measurable residual disease (MRD) assay, which can detect parts-per-million (ppm) levels of circulating tumor DNA (ctDNA) using minimal sequencing. We applied MAESTRO to 140 samples from 28 patients (15 durable responders at 12 months and 13 nonresponders) to identify treatment failure after axicabtagene ciloleucel (axi-cel), administered at our institution between 2018 and 2022. Responder and nonresponder patients had similar baseline tumor burden. By 1 week after infusion, responders had marked ctDNA reduction compared to nonresponders (P < .001). At weeks 2 and 4, responders had ctDNA levels approaching 0 ppm, whereas nonresponders had persistence of ctDNA (each P < .001). At day 0, up to 21% of patients had ctDNA fractions <0.01%; hence, these individuals would not have qualified for ctDNA monitoring with a less sensitive test. Our results confirm the feasibility of highly sensitive MRD detection by ctDNA for early identification of patients at high risk of disease progression from axi-cel.


  • Open Access

    Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade

    by Reid W. Merryman, Justin Kline, Robert A. Redd, Harrison Olszewski, Emma Welsh, Kathleen Pfaff, Hannah Lee, Mikaela McDonough, Inhye E. Ahn, Jennifer R. Brown, et al.